Satsuma Pharmaceuticals Inc

Company Profile

Satsuma Pharmaceuticals Inc had its IPO on 2019-09-13 under the ticker symbol STSA.

The company operates in the Healthcare sector and Biotechnology industry. Satsuma Pharmaceuticals Inc has a staff strength of 25 employees.

Stock update

Shares of Satsuma Pharmaceuticals Inc opened at $1.11 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.01 - $1.14, and closed at $1.1.

This is a -0.9% slip from the previous day's closing price.

A total volume of 1,829,701 shares were traded at the close of the day’s session.

In the last one week, shares of Satsuma Pharmaceuticals Inc have increased by +4.27%.

Satsuma Pharmaceuticals Inc's Key Ratios

Satsuma Pharmaceuticals Inc has a market cap of $36.80 million, indicating a price to book ratio of 0.4202 and a price to sales ratio of 0.

In the last 12-months Satsuma Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-53894500. The EBITDA ratio measures Satsuma Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Satsuma Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -49.62% with a return of equity of -104.04%.

In Q1, Satsuma Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Satsuma Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.99 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Satsuma Pharmaceuticals Inc’s profitability.

Satsuma Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.5742. Its price to sales ratio in the trailing 12-months stood at 0.

Satsuma Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$43.48 million

Total Liabilities

$5.83 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

Satsuma Pharmaceuticals Inc ended 2024 with $43.48 million in total assets and $0 in total liabilities. Its intangible assets were valued at $43.48 million while shareholder equity stood at $37.65 million.

Satsuma Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $5.83 million in other current liabilities, 3000.00 in common stock, $-222085000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $19.53 million and cash and short-term investments were $41.37 million. The company’s total short-term debt was $116,000 while long-term debt stood at $0.

Satsuma Pharmaceuticals Inc’s total current assets stands at $43.38 million while long-term investments were $0 and short-term investments were $21.84 million. Its net receivables were $0 compared to accounts payable of $874000.00 and inventory worth $0.

In 2024, Satsuma Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Satsuma Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.1

52-Week High

$8.08

52-Week Low

$0.59

Analyst Target Price

$2

Satsuma Pharmaceuticals Inc stock is currently trading at $1.1 per share. It touched a 52-week high of $8.08 and a 52-week low of $8.08. Analysts tracking the stock have a 12-month average target price of $2.

Its 50-day moving average was $0.97 and 200-day moving average was $2.38 The short ratio stood at 0.05 indicating a short percent outstanding of 0%.

Around 1042.9% of the company’s stock are held by insiders while 5790.1% are held by institutions.